Iodine-123-β-CIT and iodine-123-FPCIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson's patients

Journal of Nuclear Medicine

Volumn 39, Issue 9, 1998, Pages 1500-1508

  Seibyl, John P ^a   Marek, Kenneth ^b   Sheff, Kimberly ^b   Zoghbi, Sami ^b   Baldwin, Ronald M ^b   Charney, Dennis S ^b   Van Dyck, Christopher H ^b   Innis, Robert B ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

Dopamine; Dopamine transporter; Iodine 123 carbomethoxy 3 (4 iodophenyltropane); Iodine 123 FP carbomethoxy 3 (4 iodophenyltropane); Parkinson's disease; SPECT

Indexed keywords

BETA CARBOMETHOXY 3 BETA (4 IODOPHENYLTROPANE) I 123; DOPAMINE TRANSPORTER; FLUOROPROPYL BETA CARBOMETHOXY 3 BETA (4 IODOPHENYLTROPANE) I 123; IODINE 123; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BRAIN REGION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG UPTAKE; FEMALE; HUMAN; IMAGE ANALYSIS; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TISSUE DISTRIBUTION;

AGED; CARRIER PROTEINS; CASE-CONTROL STUDIES; COCAINE; CORPUS STRIATUM; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; NERVE TISSUE PROTEINS; PARKINSON DISEASE; TIME FACTORS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TROPANES;

EID: 0031684335     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. 123I]β-CIT): high affinity SPECT radiotracer of monoamine reuptake sites in brain. J Med Chem 1991;34:3144-3146.
2. Innis R, Seibyl J, Scanley B, et al. SPECT imaging demonstrates loss of striatal monoamine transporters in Parkinson's disease. Proc Natl Acad Sci USA 1993;90: 11965-11969.
3. 123I]β-CIT: pharmacological characterization of brain uptake in nonhuman primates. Synapse 1993;13:295-309.
4. 123I]β-CIT in healthy human subjects. J Nucl Med 1994;35:764-770.
5. 123I]β-CIT binding to dopamine transporters in healthy human subjects. J Cereb Blood Flow Metab 1994;14:982-994.
6. 123I-β-CIT SPECT. J Nucl Med 1995;36:1175-1181.
7. 123I]β-CIT striatal uptake correlates with symptom severity in Parkinson's disease. Ann Neurol 1995;38:589-598.
8. 123-I]-β-CIT SPECT. Parkinsonism Rel Disord 1995;1:47-51.
9. 123I]β-CIT binding kinetics in the human brain. J Neural Transm Gen Sect 1993;94:137-146.
10. Asenbaum S, Brucke T, Pirker W, et al. Imaging of dopamine transporters with iodine-123-β-CTT and SPECT in Parkinson's disease. J Nucl Med 1997;38:1-6.
11. Marek K Seibyl J, Zoghbi S, et al. Iodine-123 β-CIT SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-parkinson's disease. Neurology 1996;46:231-237.
12. 123I]-β-CIT SPECT brain measurement of dopamine transporters in healthy human subjects. J Nucl Med 1996;37:222-228.
13. 123I)β-CIT in nonhuman primates: pharmacokinetics, biodistribution and SPECT brain imaging coregistered with MRI. Nucl Med Biol 1993;20:597-606.
14. 123I]-β-CIT. J Nucl Med 1996;37:1129-1133.
15. 123I]-FCIT SPECT in the demonstration of the dopaminergic deficit in Parkinson's disease. Eur J Nucl Med 1997;24:68-71.
16. Kuikka J, Bergstrom K, Ahonen A, et al. Comparison of iodine-123 labeled 2β-carbomethoxy-3β-(4-iodophenyl)tropane and 2β-carbomethoxy-3β-(4-iodophenyl)-N-(3-flouropropyl)nortropane for imaging of the dopamine transporter in the living human brain. Eur J Nucl Med 1996;22:356-360.
17. Fahn S, Elton R, and members of the UPDRS development committee Unified Parkinson's disease rating scale. In: Fahn S, Marsden, CD, Calne, DB, Goldstein, M, eds. Recent developments in Parkinson's disease. Florham Park, NJ: Macmillan Healthcare Information; 1987:153-164.
18. Chang LT. A method for attenuation correction in computed tomography. IEEE Trans Nucl Sci 1987;NS-25:638-643.
19. 11C-methyl]-(-)cocaine PET studies in human subjects J Cereb Blood Flow Metab 1990;10:740-747.
20. Gandelman M, Baldwin RM, Zoghbi SS, Zea-Ponce Y, Innis RB. Evaluation of Ultrafiltration for the free fraction determination of SPECT radiotracers: β-CIT, IBF, and iomazenil. J Pharm Sci 1994;83:1014-1019.
21. Pirker W, Asenbaum S, Kasper S, et al. β-CIT SPECT demonstrates blockade of 5HT-uptake sites by citalopram in the human brain in vivo. J Neural Transm 1995;100:247-256.
22. 3H]citalopram. Neuroscience 1993;54: 691-699.
23. 123I]-β-CIT in human plasma may obstruct quantitation of the dopamine transporter. Synapse 1995;19:297-300.
24. 123I]-β-CIT determined with a gradient HPLC method. Nucl Med Biol 1995;22:971-976.
25. 123I labeled β-FPCITand β-CIT-FE metabolism measured in monkey and human plasma -identification of two labeled metabolites with HPLC. Hum Psychopharm 1996;11: 483-490.
26. 123,124I]-β-CIT, plasma analysis and pharmacokinetic studies with SPECT and PET. Nucl Med Biol 1995;22:977-984.
27. Iwasaki Y, Yonekura Y, Saji H, et al. SPECT imaging of dopamine D2 receptors with 2′ iodospiperone. J Nucl Med 1995;36:1191-1195.
28. 123I labeled 2β carbomethoxy-3β-(4-iodophenyl)tropane (β-CIT) derivatives and their labeled metabolites in monkey and human plasma determined by gradient HPLC. J Label Comp Radiopharm 1995;37:706-708.
29. 123I-]-β-CIT in plasma of human and nonhuman primates. Synapse 1997;25:306-308.
30. 18F]cyclofoxy and positron emission tomography. J Cereb Blood Flow Metab 1993;13:24-42.
31. 11C] raclopride binding to D2 dopamine receptors studies with PET - a comparison to the equilibrium analysis. J Cereb Blood Flow Metab 1989;9:696-708.